Patent intelligence · US
US 12428480
Anti-CD19 antibodies and multi-specific binding proteins
Anti-CD19 antibodies and multi-specific binding proteins
Patent details — US 12428480
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 30, 2025
- Expiration
- Sep 25, 2045
- Applicant
- Cullinan Therapeutics, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61P, A61P31/04
Quick answer
US 12428480 (Anti-CD19 antibodies and multi-specific binding proteins) is held by Cullinan Therapeutics, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cullinan Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K2039/505, A61P, A61P31/04, A61P35/00, A61P35/02
More from Cullinan Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12428480?
US 12428480 (Anti-CD19 antibodies and multi-specific binding proteins) is held by Cullinan Therapeutics, Inc.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12428480?
Cullinan Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 12428480 expire?
Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.